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Abstract 
Review on ABCC10, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: EST182763, MRP7, SIMRP7 




Contains 22 exons and 21 introns (Kao et al., 2003). 
Description 
The gene encompasses 23065 bases. 
Transcription 
Transcript is 744 bps, and has 10 splice variants. 
In normal tissue 
A study of the ABCC10 promoter revealed that the 
presence of E2F and Sp1 sites are required for 
maximum transcription.  
In addition other elements were found in the 
promoter including: cAMP-responsive element 
binding protein, estrogen receptor binding site, 
hepatic nuclear factor, progesterone receptor 
binding site, and sterol regulatory element binding 
protein (Dabrowska and Sirotnak, 2004). 
ABCC10 transcript is widespread at low levels  
(Hopper et al., 2001; Maher et al., 2005) with 
highest expression in the pancreas. Decreased 
expression is observed in activated resting T and B 
cells (Takayanagi et al., 2004). 
In cancer 
In cell lines: In terms of cancer, the ABCC10 gene 
is expressed in human tumor cell lines, HepG2, 
CWR22RV1 and TSU-PR1 at greater or equal 
levels than ABCC1, ABCC2 and ABCC3. Novel 
ABCC10 transcripts have been identified in 
HepG2, and CWR22RV1 cells. These transcripts 
are heterogeneic and imply complexity in the exons 
and introns of this region (Dabrowska and Sirotnak, 
2004). 
In breast cancer: ABCC10 transcript is upregulated 
in breast tumors treated with 5-fluorouracil, 
anthracycline, cyclophosphamide or taxane based 
neoadjuvant chemotherapy in comparison with 
normal tissue. Further, ABCC10 transcript 
expression is associated with ER positive breast 
cancer (Hlavac et al., 2013). 
In acute myeloid leukemia: ABCC10 transcript is 
also expressed in acute myeloid leukemia (Hu et al., 
2011). 
In hepatocellular carcinoma: Transcripts from 
ABCC10 and various other transporters including: 
ABCB6, ABCC1, ABCC4, ABCC5, and ABCC12 
are upregulated in over 50% hepatocellular 
carcinoma in untreated patients. It was also 
observed that microRNA let-7a/e is able to 
downregulate ABCC10 transcript (Borel et al., 
2012). 











Unglycosylated ABCC10 is ~158 kDa (Hopper et 
al., 2001). 
ABCC10, like ABCC1, 2, 3 and 6 (see figure above 
A) has an N-terminal membrane spanning domain 
(MSD) that is not present in ABCC4, 5, 11 or 12 
(figure above B). All ABCC subfamily members 
contain two Nucleotide Binding Domains (NBD). 
Expression 
ABCC10 has been detected in various human 
occular-absorption barrier tissues including, the iris 
ciliary body, corneal epithelium, conjuntive 
epithelium, and retina (Chen et al., 2013). 
ABCC10 is expressed in cell lines derived from 
acute myeloid leukemia (Hu et al., 2011). 
Localisation 
Localizes basolaterally in ABCC10-transfected 
LLC-pK1 cells (Malofeeva et al., 2012). 
Function 
In vitro 
ABCC10 transports estrogen β glucuronide, and 
exhibits modest transport of leukotrienes. Similar to 
other subfamily members ABCC10 can efflux 
lipophilic anions (Chen et al., 2003). 
ABCC10 is a drug efflux pump that is able to 
mediate transport of taxanes in vivo. In vitro studies 
have shown that ABCC10 confers resistance to a 
variety of hydrophobic drugs, including paclitaxel, 
docetaxel, vincristine, vinblastine, epothilone B, 
cytarabine, in a glutathione independent manner 
(Hopper-Borge et al., 2004; Hopper-Borge et al., 
2009). 
Prior work has shown that ABCC10 may have a 
role in natural killer cell mediated lysis. A report 
demonstrated that a peptide derived from ABCC10 
binds to HLA-E and inhibits NK cell-mediated lysis 
in a CD94 and class I-dependent fashion (Wooden 
et al., 2005). 
ABCC10 ATPase activity is stimulated by estradiol 
glucuronide, leukotriene, tamoxifen, docetaxel and 
ARA-C (Malofeeva et al., 2012). 
In vivo 
Abcc10 protects thymus, spleen and bone marrow 
when exposed to paclitaxel in vivo.  
Abcc10 loss promotes loss of white blood cells, 
increased weight loss and increased lethality in 
mice exposed to high doses of paclitaxel (Hopper-
Borge et al., 2011). 
Homology 
ABCC10 exhibits structural and/or functional 
homology with other ABC transporters: CFTR, 
ABCC1, ABCC2, ABCC3, ABCC6.  
However, ABCC10 shares the lowest amino acid 
identity (33.8%) to ABCC1 compared to ABCC2, 
ABCC3, ABCC4, ABCC5 and ABCC6 (Hopper et 
al., 2001). 
ABCC10 is present in many species including: 
drosophila melanogaster, xenopus, saccharomyces 
cerevisiae, danio rerio, sus scrofa, mus musculus, 
latimeria chalumnae, felis catus, bos taurus, 
tetranychus urticae (Schippert et al., 2008; 
Dermauw et al., 2013).  
ABCC10 is present in all placental mammals, 
similar to other subfamily members, ABCC1, 
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ABCC3, ABCC4-7, and ABCC9 (Moitra and Dean, 
2011). 
Implicated in 
Non small cell lung cancer 
Note 
In vitro cellular resistance in non small cell lung 
cancer. ABCC10 expression is a predictive 
biomarker for the resistance to paclitaxel in non-
small cell lung cancer (Oguri et al., 2008). 
ABCC10/MRP7 expression is associated with 
vinorelbine resistance in non-small cell lung cancer 
(Bessho et al., 2009).  
Another study implicated ABCC10 in gemcitabine 
resistance mechanisms in non small cell carcinoma 
cell lines (Ikeda et al., 2011). 
ABCC10 is overexpressed in NSCLC. The 
expression of ABCC10 in adenocarcinoma is higher 
than in squamous cell carcinoma.  
ABCC10 expression in adenocarcinoma correlates 
with pathological grades and TNM stages (Wang et 
al., 2009). 
Head and neck cancer 
Note 
Multidrug resistance protein 7 expression is 
involved in cross-resistance to docetaxel in salivary 




A ovarian carcinoma xenograft model demonstrated 
that intermittant docetaxel dosing of tumors 
promotes upregulation of MRP7 and other drug 
resistance genes including btubulin III, Akt2, and 
thioredoxin.  
However, when the dosing was continuous the 
various resistance genes did not upregulate (De 
Souza et al., 2011). 
Acute myeloid leukemia 
Note 
ABCC10 may play a role in Ara-C resistance 
mechanisms in acute myeloid leukemia (Hu et al., 
2011). ABCC10 transcript is more highly expressed 
in childhood AML than in many normal samples 
(Steinbach et al., 2006). 
Breast cancer 
Note 
In metastatic breast cancer, a difference in 
progression-free survival (PFS) was found between 
circulating stem cells (CTCs) positive and CTCs-
negative patients. PFS was shorter in patients 
whose CTCs expressed two or more ABCC 
subfamilies, including ABCC10 (Gradilone et al., 
2011). 
ABCC10 expression may confer therapeutic 
resistance in solid breast tumors (submitted, 
Domanitskaya et al.). 
Colorectal cancer 
Note 
An inverse correlation between ABCC10 transcript 
and tumor aggressiveness and tumor grade severity 
was found in colorectal cancer (Hlavata et al., 
2012). 
Human immunodeficiency virus 
Note 
ABCC10 polymorphisms contribute to the 
development of kidney tubular dysfunction (KTD) 
in some HIV patients (Giacomet et al., 2013). 
ABCC10 polymorphisms modulate blood levels of 
the anti HIV drugs tenofivir, and nevapirine 
(Pushpakom et al., 2011; Liptrott et al., 2012). 
Parkinson's disease 
Note 
ABCC10 inhibits methylmercury-associated animal 
toxicity and dopaminergic neurodegeneration in 
Caenorhabditis elegans (Vanduyn and Nass, 2014). 
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